Bristol-Myers Squibb Company (BMY)

FDA Approves Bristol Myers (NYSE: BMY) Mavacamten NDA for Review

Bristol-Myers Squibb Company (NYSE: BMY) disclosed Friday that FDA has acknowledged the New Drug Application (NDA) of Mavacamten. FDA has decided to review the NDA of Mavacamten which is an investigational drug for the cure of the cardiac condition.

Schrodinger (NASDAQ: SDGR) Signs Drug Discovery Deal With Bristol Myers

Schrodinger Inc. (NASDAQ: SDGR ) declared that it has signed a drug discovery deal with Bristol Myers Squibb (NYSE: BMY). This collaboration contract will make Schrodinger qualified for the identification of development candidates and Bristol Myers will be liable for the development of the candidate